# COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg

> **NCT04428684** · PHASE1 · COMPLETED · sponsor: **Peptigroupe Inc.** · enrollment: 80 (actual)

## Conditions studied

- Dysfunctional Uterine Bleeding

## Interventions

- **DRUG:** Pepti 3.6 mg

## Key facts

- **NCT ID:** NCT04428684
- **Lead sponsor:** Peptigroupe Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-29
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-06-07
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428684, "COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04428684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*